Biosimilar Litigation: Janssen Vs. Samsung Anticipates Supreme Court Decision
Executive Summary
Hoping to hold off a biosimilar to Remicade, Janssen challenges Samsung's decision not to participate in patent dance as it claims infringement of three manufacturing patents.
You may also be interested in...
Samsung's Biosimilar Manufacturing Documents Lead Janssen To Drop Infringement Suit
Janssen concludes the manufacturing processes for Renflexis do not infringe its Remicade patents, clearing Samsung and partner Merck from potential damages resulting from their at-risk launch of the biosimilar; innovator's legal action remains against Inflectra partners Pfizer and Celltrion.
Samsung's Biosimilar Manufacturing Documents Lead Janssen To Drop Infringement Suit
Janssen concludes the manufacturing processes for Renflexis do not infringe its Remicade patents, clearing Samsung and partner Merck from potential damages resulting from their at-risk launch of the biosimilar; innovator's legal action remains against Inflectra partners Pfizer and Celltrion.
Biosimilar Launches Depend Mostly On Patents After Supreme Court Ruling
US high court says biosimilar sponsors do not have to wait until after FDA approval to start countdown clock for marketing, but patent litigation may impede launches.